Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag AIM ImmunoTech's Ampligen drug in combo with Imfinzi shows promise in late-stage pancreatic cancer trial with positive results and tolerability.

flag AIM ImmunoTech has announced promising preliminary results from a Phase 1b/2 trial of its drug Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. flag The therapy was well-tolerated, with no severe side effects noted. flag Notably, two of three patients in the initial group reached the six-month stability assessment. flag AIM ImmunoTech specializes in treatments for cancer, immune disorders, and viral diseases.

4 Articles